Creative Medical Technology (CMT) will commence commercialization of StemSpine®, a regenerative stem cell procedure for the treatment of degenerative disc disease, in the U.S. in coming weeks. The procedure has been employed successfully ex-U.S. with over 12 months of data showing safety and efficacy.
The patented procedure offers a drug-free alternative for the treatment of chronic lower back pain using a patient's own stem cells.
"As we've previously announced it was our goal to commercialize StemSpine in 2019, so we're pleased with the progress of this technology and the value it brings to our company as domestic commercialization begins," said Timothy Warbington, President and CEO.
CMT's technology uses biologic elements to stimulate development of new blood vessels and counteract deficient circulation that may contribute to disc degeneration. By increasing circulation, CMT expects to modify the disc environment to give injected stem cells optimal conditions for regeneration.